Market Research Future (MRFR) has published a detailed report stating that the global gestational diabetes market is marked to expand moderately at a CAGR of 5.4% during the forecast period of 2017-2023.
Gestational Diabetes is one of the major health problems across the globe. Diabetes is a metabolic disorder in which there is decrease in the level of insulin which ultimately causes increase in the blood sugar level. Gestational diabetes starts when the body is unable to secrete and use all the insulin needed during pregnancy due to which the glucose builds up in the blood to alarmingly high levels. Global gestational diabetes market is driven because of increasing diabetic population.
Moreover, governmental initiatives for research & development, rising demand for the better treatment and changing lifestyle habits have fueled the growth of the market. Obesity, overweight and smoking increases the possibility of the diabetes. Due to sedentary lifestyle and poor diet, the number of obese population has increased which is also contributed in the growth of the market. On the other hand, lack of awareness and high cost of treatment may responsible for restraining the market.
Fill Out Details To Receive FREE Sample Here@ https://www.marketresearchfuture.com/sample_request/4591
The global gestational diabetes market has been segmented on the basis of types, administration, treatment, and end users. Based on types, the gestational diabetes market has been segmented into type A1, type A2, and others. Based on administration, the gestational diabetes market has been segmented into oral, intravenous, and other. Based on treatment, the gestational diabetes market has been segmented into monitoring, drug treatment, and non-pharmacological treatment.
The monitoring segment has been sub-segmented into urinary glucose testing, oral glucose tolerance test, and others. The drug treatment segment has been sub-segmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others. Based on end users, the gestational diabetes market has been segmented into hospital, retail pharmacy and other.
The Americas commands the major share of the market owing to the large patient population, strong government support for research & development, and high healthcare spending. According to the America Diabetic Association, 29 million Americans were suffering from diabetes which is 9.3% of total America population, among this nearly 50% of patient are women. Moreover, changing lifestyle and poor diet has fuelled the growth of the market.
Europe has the second leading market in global gestational diabetes market which is followed by Asia Pacific. Asia Pacific is the fastest growing market for gestational diabetes. As per statistics, more than 55% of diabetics in the world live in Asia Pacific region. China and India contribute a major share in the Asia Pacific diabetes drug market due to presence of huge diabetic population. Rapidly increasing diabetic and obese population and development in healthcare sector has created a major market for the gestational diabetes.
The Middle East and Africa contribute the least in the market of global gestational diabetes market. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition. However the growth of the Africa market is high due to presence of opportunities for the development of the market.
The global gestational diabetes market is segmented on the basis of types, administration, treatment, and end users.
On the basis of types, the market is segmented into type A1, type A2, and others.
On the basis of administration, the market is categorized into oral, intravenous, and other.
On the basis of treatment, the market is segmented into monitoring, drug treatment, and non-pharmacological treatment. Monitoring is further segmented into urinary glucose testing, oral glucose tolerance test, and others. Drug treatment is sub-segmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others
On the basis of end users, the market is segmented into hospitals, retail pharmacy, and other.
Get PDF with Technological Advancement @ https://www.marketresearchfuture.com/reports/gestational-diabetes-market-4591
Market Key Players:
- Antares Pharma (US),
- INJEX Pharma AG (Germany)
- 3M (US), Eli Lilly (US)
- Biocon (US)
- Sunpharma (India)
- Sanofi (France)
- Novo Nordisk (Denmark)
- Abbott (US)
- AstraZeneca (UK)
- Novartis (Switzerland)
- Daiichi Sankyo (Japan)
- Boehringer Ingelheim (Germany)
- Merck & Co. (US)
- Pfizer (US)
- Akros Pharma (US)
- Amgen (US)
- Adocia (France)
- Peptron (South Korea)
- Takeda (Japan)
Some Points form TOC for Gestational Diabetes Market Research Report – Forecast to 2023
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Get Excusive Discount @ https://www.marketresearchfuture.com/check-discount/4591
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312